OTCMKTS:DSRLF DiaSorin (DSRLF) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free DSRLF Stock Alerts $107.40 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$107.40▼$107.4050-Day Range$88.45▼$107.4052-Week Range$86.00▼$120.00VolumeN/AAverage Volume5 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartShort InterestStock AnalysisChartShort Interest Get DiaSorin alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About DiaSorin Stock (OTCMKTS:DSRLF)DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.Read More DSRLF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DSRLF Stock News HeadlinesDecember 8, 2023 | morningstar.comDiasorin SpA DIAJuly 27, 2023 | msn.comDiaSorin S.p.A. reports 1H resultsApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.May 9, 2023 | msn.comDiaSorin confirms 2023 guidance after Q1 resultsApril 6, 2023 | barrons.comDiaSorin S.p.A.March 29, 2023 | seekingalpha.comDiaSorin S.p.A. (DSRLF) Q4 2022 Earnings Call TranscriptMarch 4, 2023 | seekingalpha.comDiaSorin: Overvalued Italian Healthcare CompanyFebruary 15, 2023 | wsj.comCytek(R) Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorinApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 13, 2023 | finance.yahoo.comCytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorinOctober 31, 2022 | reuters.comDIAS.MI - DiaSorin SpA | Stock Price & Latest News | ReutersAugust 8, 2022 | seekingalpha.comDiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q2 2022 Results - Earnings Call TranscriptOctober 23, 2021 | finance.yahoo.comSouthwest Airlines Company (LUV) stock forecast and price targetAugust 2, 2021 | seekingalpha.comDiaSorin S.p.A. 2021 Q2 - Results - Earnings Call PresentationSee More Headlines Receive DSRLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaSorin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:DSRLF CUSIPN/A CIKN/A Webwww.diasoringroup.com Phone391614871FaxN/AEmployees3,386Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.43 billion Price / SalesN/A Cash Flow$9.09 per share Price / Cash Flow11.82 Book Value$29.27 per share Price / Book3.67Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.27 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Carlo Rosa (Age 58)CEO, GM & Executive Director Comp: $1.87MDr. Chen Menachem Even (Age 61)Chief Commercial Officer, Senior Corporate VP of Commercial Operations & Executive Director Comp: $912.75kMr. Piergiorgio Pedron (Age 53)Senior Corporate VP, CFO & Corporate Accounting Documents Officer Mr. Fabrizio Piercarlo BonelliCorporate VP & Chief Technology OfficerDr. Riccardo FavaCorporate Vice President of Communication & Investor RelationsMr. Ulisse SpadaCorporate VP, Head of the Legal Department, Secretary & General CounselMr. Stefano Ronchi (Age 64)Senior Corporate Vice President of Human Resources Mr. Angelo Rago (Age 61)President of Luminex Corporation More ExecutivesKey CompetitorsbioMérieuxOTCMKTS:BMXMFMDxHealthNASDAQ:MDXHPharma MarOTCMKTS:PHMMFRecordati Industria Chimica e FarmaceuticaOTCMKTS:RCDTFRespiriOTCMKTS:KMLXFView All Competitors DSRLF Stock Analysis - Frequently Asked Questions How have DSRLF shares performed in 2024? DiaSorin's stock was trading at $99.7828 at the start of the year. Since then, DSRLF shares have increased by 7.6% and is now trading at $107.40. View the best growth stocks for 2024 here. Are investors shorting DiaSorin? DiaSorin saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 537,600 shares, an increase of 11.2% from the March 15th total of 483,400 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days. View DiaSorin's Short Interest. How do I buy shares of DiaSorin? Shares of DSRLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:DSRLF) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsMan Who Predicted 2008: “This Will be Worse.”AltimetryYou Won't Believe Who Bezos is Working With to Fight Alzheimer'sBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaSorin S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.